The estimated Net Worth of Jennifer Jarrett is at least $13.9 Million dollars as of 27 March 2024. Ms Jarrett owns over 11,551 units of Arcus Biosciences Inc stock worth over $3,652,843 and over the last 7 years she sold RCUS stock worth over $9,603,389. In addition, she makes $603,171 as COO & Director at Arcus Biosciences Inc.
Ms has made over 20 trades of the Arcus Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 11,551 units of RCUS stock worth $202,720 on 27 March 2024.
The largest trade she's ever made was selling 58,625 units of Arcus Biosciences Inc stock on 26 February 2024 worth over $1,177,776. On average, Ms trades about 7,157 units every 21 days since 2017. As of 27 March 2024 she still owns at least 215,253 units of Arcus Biosciences Inc stock.
You can see the complete history of Ms Jarrett stock trades at the bottom of the page.
Jennifer Jarrett M.B.A. is the COO & Director at Arcus Biosciences Inc.
As the COO & Director of Arcus Biosciences Inc, the total compensation of Ms A at Arcus Biosciences Inc is $603,171. There are 3 executives at Arcus Biosciences Inc getting paid more, with William Grossman having the highest compensation of $3,400,310.
Ms A is 50, she's been the COO & Director of Arcus Biosciences Inc since . There are 10 older and 3 younger executives at Arcus Biosciences Inc. The oldest executive at Arcus Biosciences Inc is Yasunori Kaneko, 66, who is the Lead Independent Director.
Jennifer's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead und Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Arcus Biosciences Inc executives and other stock owners filed with the SEC include: